Back to Trials
NCT04336644NARecruiting

Continuous Versus Intermittent cARdiac Electrical moNitorinG

Washington University School of Medicine

Start Date

11/21/2023

Completion Date

12/31/2026

Summary

The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment) * At least 18 years of age. * No allergy to adhesive patches. * Able to understand and willing to sign an IRB-approved written informed consent document. Exclusion Criteria: * Younger than 18 years of age * Allergy to adhesive patches

Interventions

DEVICE

BodyGuardian Mini Plus

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Torsades de Pointe Caused by DrugLong QT Syndrome

Locations

Washington University School of Medicine

St Louis, Missouri 63110

United States